Kymera director granted options on 6,068 shares

Kymera Therapeutics director Pamela Esposito received a new stock option grant.

Accepted by SEC EDGAR 06/25/2026 - 06:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kymera Therapeutics director Pamela Esposito received a new stock option grant. She was granted options covering 6,068 shares of Kymera Therapeutics common stock at an exercise price of $99.87 per share, with no cash paid for the grant itself.

The option vests in full on the earlier of June 24, 2027 or the date of the company’s next annual stockholder meeting, aligning vesting with her continued board service. Following this award, Esposito holds derivative securities representing 6,068 underlying common shares according to this filing.

Insider Trade Summary

Grant/Award: 6,068 shares

Grant/Award 1 txn

Insider Esposito Pamela

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,068	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,068 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 6,068 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Key Figures

Option grant size: 6,068 shares Exercise price: $99.87 per share Post-transaction derivative holdings: 6,068 shares +3 more

6 metrics

Option grant size 6,068 shares Stock Option (Right to Buy) underlying common stock

Exercise price $99.87 per share Conversion or exercise price of stock option

Post-transaction derivative holdings 6,068 shares Total shares underlying options following transaction

Vesting date June 24, 2027 Full vesting or earlier on next annual stockholder meeting date

Option expiration June 23, 2036 Expiration date of stock option grant

Transaction price per option $0.00 No cash paid to receive the option grant

Key Terms

Stock Option (Right to Buy), Common Stock, exercise price, vest in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 99.8700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares underlying this stock option shall vest in full upon the earlier"

annual meeting of the Issuer's stockholders financial

"the date of the next annual meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pamela Esposito do in this Form 4 for Kymera Therapeutics (KYMR)?

Pamela Esposito reported receiving a stock option grant for 6,068 shares of Kymera Therapeutics common stock. The options were awarded as compensation, not bought in the market, and give her the right to purchase shares at a fixed exercise price.

How many Kymera Therapeutics (KYMR) shares are covered by the new stock options?

The new stock option grant covers 6,068 underlying shares of Kymera Therapeutics common stock. These options provide potential future ownership if exercised, but do not represent an immediate purchase or sale of common shares in the open market.

What is the exercise price of Pamela Esposito’s Kymera Therapeutics options?

The exercise price for the reported Kymera Therapeutics stock options is $99.87 per share. This is the fixed price at which she can buy the 6,068 underlying common shares if she chooses to exercise the options in the future.

When do Pamela Esposito’s Kymera Therapeutics stock options vest?

The options vest in full on the earlier of June 24, 2027 or the date of Kymera Therapeutics’ next annual stockholder meeting. Full vesting must occur before she can exercise the options to acquire the underlying common shares.

Is this Kymera Therapeutics Form 4 a market purchase or sale of shares?

This Form 4 reflects a grant of stock options, not a market purchase or sale of Kymera Therapeutics shares. Esposito received the options as a compensation-related award, with no open-market buying or selling disclosed in this specific filing.

How many derivative securities does Pamela Esposito hold after this Kymera grant?

After this transaction, the filing shows Esposito holding derivative securities tied to 6,068 underlying Kymera Therapeutics common shares. This amount equals the newly granted options, indicating the reported position is entirely from this award in the current Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Esposito Pamela

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$99.87	06/24/2026		A		6,068		(1)	06/23/2036	Common Stock	6,068	$0	6,068	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)